Eli Lilly
Activity
Eli Lilly to Acquire Kelonia Therapeutics for $3.25 Billion to Boost Oncology Portfolio
Eli Lilly announced its acquisition of Kelonia Therapeutics for over $3 billion, aiming to strengthen its oncology and CAR-T therapy portfolio. This strategic move reflects Lilly's focus on expanding its presence in cancer treatment and genetic medicines.
Eli Lilly Acquires Kelonia for $3.25 Billion to Strengthen Cancer and Autoimmune Treatment R&D
Eli Lilly is acquiring Kelonia Therapeutics for $3.25 billion, aiming to advance cell therapies for cancer and autoimmune diseases. The deal underscores Lilly's strategy to lead in innovative biotech and cancer treatment development.
FDA requests further safety data from Eli Lilly on Foundayo's liver injury risks
The FDA has requested additional safety information from Eli Lilly regarding liver injury concerns linked to Foundayo. This step indicates heightened regulatory scrutiny even after the drug's recent approval.
Novo Nordisk to Cut U.S. Prices of Key Obesity Drugs, Stocks Dip as Competitors Gain Edge
Novo Nordisk is planning to cut the U.S. list prices of Wegovy by 50% starting in 2027. Meanwhile, Eli Lilly has gained an advantage in the obesity drug market with its recent product launch, while Novo's new drug trials lag behind.
India's Obesity Drug Market Shifts Post-Novo Nordisk Patent Expiry
India's market share for Novo Nordisk's obesity drug has grown as generics surge after patent expiry. Eli Lilly's Mounjaro faces declining sales amid rising competition, reshaping the weight-loss drug landscape.
FDA Approves Eli Lilly's Foundayo Oral GLP-1 for Weight Management
The FDA has approved Eli Lilly's new oral GLP-1 weight-loss medication, Foundayo, for adults with obesity or overweight. This approval introduces a convenient pill option that could significantly shift weight management treatments and market dynamics.
FDA approves 7.2 mg Wegovy boosting weight loss 21%; Indian generics cut prices to $14/month
The FDA approved a triple-strength 7.2 mg dose of Wegovy, enabling patients to lose 21% body weight on average. Simultaneously, Indian companies launched significantly cheaper generic versions of semaglutide drugs, broadening global access and upping market competition.
Trump enforces 100% tariffs on imported patented drugs, seeks U.S. manufacturing boost
The Trump administration has enacted a 100% tariff on certain imported patented drugs to boost U.S. pharmaceutical manufacturing and reduce foreign dependency. The policy includes incentives for domestic production but may have significant global trade implications, particularly for countries like India.
Eli Lilly’s FDA-Approved Obesity Drug Foundayo Challenges Wegovy's Market Lead
Eli Lilly’s FDA-approved oral obesity drug Foundayo offers a convenient alternative to Wegovy, intensifying competition in the weight-loss medication market and expanding patient options.
Eli Lilly and Biogen Announce Major Biotech Acquisitions, Boosting Market Confidence
Eli Lilly and Biogen are acquiring Centessa Pharma and Apellis Pharma, respectively, propelling biotech stocks upward. These major deals underscore ongoing industry consolidation amidst mixed approval signals and shifting market dynamics.
Eli Lilly Acquires Centessa Pharmaceuticals for $6.3B in Sleep Disorder Focus
Eli Lilly is acquiring Centessa Pharmaceuticals for $6.3 billion, focusing on sleep and wakefulness disorder treatments. The deal reflects Lilly’s strategy to strengthen its portfolio amid international pricing and U.S. policy pressures.
Eli Lilly Gains Rights to AI-Discovered Drugs in $2.75B Deal with Insilico
Eli Lilly's $2.75 billion deal with Insilico Medicine now includes rights to develop and sell specific AI-discovered drug candidates, notably those targeting GLP-1 for oral use. This development underscores Lilly’s commitment to AI in drug innovation and signals a move toward more targeted therapies.
Merck to Acquire Terns Pharmaceuticals for $6.7B as Lilly Elevates Former Loxo Executives
Merck plans to acquire Terns Pharmaceuticals for $6.7 billion to enhance its cancer drug pipeline ahead of Keytruda patent expiry. Meanwhile, Eli Lilly boosts its oncology leadership by promoting former Loxo executives to key roles, shaping future business strategies.
Eli Lilly’s Retatrutide Cuts Body Weight by 17%, Lowers HbA1C in Phase 3 Diabetes Trial
Eli Lilly's diabetes drug Retatrutide caused up to 17% body weight loss and nearly 2% HbA1C reduction in a Phase 3 trial. These results suggest a major advancement in diabetes treatment by addressing both blood sugar and obesity effectively.
Structure Therapeutics' Obesity Pill Achieves 16% Weight Loss in Phase 2 Trial
Structure Therapeutics announced a new oral obesity pill that resulted in a 16% weight loss after 44 weeks. This milestone signals a promising competitor to Eli Lilly and Novo Nordisk in the oral GLP-1 treatment market.
Eli Lilly Launches Employer Programs to Boost Access to Obesity Drugs
Eli Lilly has launched new programs aimed at employers to improve access to obesity drugs outside of insurance coverage. These initiatives could significantly expand patient access, especially among working adults. The move signals a strategic shift in how obesity treatments are distributed.
Chinese-Made Mazdutide Shows Promising Weight Loss Potential
Mazdutide, a new weight-loss injection from China, promises up to 15% body weight reduction. Its promising results could impact obesity treatment globally, pending further studies and approvals.
GLP-1 Medications Show Mixed Results in Weight Loss and Blood Sugar Control
Two new studies present contrasting views on GLP-1 drugs: one shows promising results in blood sugar and weight reduction, while the other highlights their temporary effects. These findings underscore the need for further research to optimize treatment plans for diabetes and obesity.